Table 4.
Unadjusted univariate analysis of factors associated with EQ-5D-3L scores (using two-part model)
| Marginal effect | 95% CI | p value* | |
|---|---|---|---|
| Age groups | 0.717 | ||
| 18–35 | – | ||
| 36–50 | − 0.004 | − 0.053, 0.046 | 0.888 |
| ≥ 51 | − 0.021 | − 0.077, 0.035 | 0.460 |
| Sex | 0.807 | ||
| Male | – | ||
| Female | − 0.003 | − 0.044, 0.038 | 0.889 |
| Aboriginal/Torres Strait Islander ethnicity | 0.242 | ||
| No | – | ||
| Yes | − 0.010 | − 0.057, 0.037 | 0.674 |
| Completed high school or higher education | 0.123 | ||
| No | – | ||
| Yes | 0.033 | − 0.008, 0.074 | 0.113 |
| Main source of income | 0.000 | ||
| No income | – | ||
| Full-time/part-time/casual employment | 0.070 | − 0.041, 0.181 | 0.215 |
| Government assistance | − 0.099 | − 0.198, 0.000 | 0.049 |
| Other | − 0.183 | − 0.325, − 0.040 | 0.012 |
| Housing | 0.259 | ||
| Stable | – | ||
| Unstable | − 0.035 | − 0.077, 0.008 | 0.110 |
| Incarceration | 0.927 | ||
| Ever (not in past 12 months) | – | ||
| In past 12 months | 0.008 | − 0.044, 0.061 | 0.759 |
| Never | 0.005 | − 0.038, 0.049 | 0.810 |
| Recency of drug injecting | 0.914 | ||
| Ever, but not in past 6 months | – | ||
| None in the past month | − 0.015 | − 0.058, 0.029 | 0.515 |
| Injected in past month | 0.000 | − 0.073, 0.073 | 0.997 |
| Hazardous alcohol consumption (AUDIT-C) | 0.223 | ||
| Never drinks | – | ||
| Low risk male/female | 0.027 | − 0.021, 0.074 | 0.271 |
| High risk male/female | − 0.010 | − 0.055, 0.035 | 0.658 |
| Smoking stats | 0.024 | ||
| Never | |||
| Previous | − 0.063 | − 0.160, 0.034 | 0.203 |
| Current | − 0.089 | − 0.163, 0.016 | 0.017 |
| Current opioid agonist therapy | 0.097 | ||
| No | – | ||
| Yes | − 0.018 | − 0.060, 0.024 | 0.409 |
| HCV RNA test result | 0.823 | ||
| Negative | – | ||
| Positive | 0.004 | − 0.036, 0.044 | 0.835 |
| Missing | − 0.022 | − 0.100, 0.056 | 0.575 |
| Self-reported HCV status | 0.591 | ||
| No | – | ||
| Yes | 0.008 | − 0.037, 0.053 | 0.718 |
| Unknown | − 0.007 | − 0.063, 0.050 | 0.812 |
| FibroScan® liver disease staging | 0.107 | ||
| F0/F1—no/mild fibrosis | – | ||
| F2/3 | − 0.048 | − 0.099, 0.003 | 0.064 |
| F4—cirrhosis | − 0.012 | − 0.087, 0.064 | 0.761 |
| Invalid score/missing | − 0.071 | − 0.166, 0.024 | 0.143 |
*The overall p-values for variables with multiple categories were derived from Wald tests, using Stata function testparm